InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,129.60
(
-0.24%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.14
(
-0.40%
)
Bitcoin
61,004.24
(
0.31%
)
Post# of 252388
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 48386

Monday, 06/11/2007 3:25:27 PM

Monday, June 11, 2007 3:25:27 PM

Post# of 252388
Re: Biogenerics

>Theresa L. Gerrard, a consultant to the Generic Pharmaceutical Association, said that biotechnology companies often tweak their processes but do clinical trials only if analytical tests show the drugs differ, she said. Moreover, she added, perfect replication is unnecessary because the drugs that Genentech produces also vary slightly from lot to lot. ''We're not asking for a lower standard,'' Dr. Gerrard said. ''We're asking to use the standard that has been in place at the F.D.A. for 15 years.'' <

Exactly! Much of what is emanating from Big Bio these days is simply anti-generic propaganda. If you applied the arguments bring promulgated by Big Bio literally, every biopharmaceutical would need a new clinical trial every time there was a new batch.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up